Liraglutide vs Semaglutide

The LEADER trial enrolled 9,340 people with type 2 diabetes and high cardiovascular risk. After a median follow-up of 3.8 years, liraglutide cut major adverse cardiovascular events by 13% (HR 0.87, 95% CI 0.78 to 0.97, PMID 27295427). That result changed how doctors thought about GLP-1 receptor agonists. Liraglutide (also sold as Victoza for diabetes and Saxenda for weight management) is a modified version of human GLP-1 with 97% amino acid homology to the native hormone. A palmitic acid chain at position 26 lets it bind albumin in the blood. That binding shields it from DPP-IV breakdown and extends the half-life from about 2 minutes to roughly 13 hours, long enough for once-daily dosing. On the weight side, the SCALE Obesity and Prediabetes trial (n=3,731, PMID 25673007) showed 8.0% mean body weight loss at 56 weeks on the 3 mg dose versus 2.6% on placebo. A head-to-head comparison in STEP 8 (PMC8753508) put those numbers in context: semaglutide 2.4 mg weekly produced 15.8% loss versus 6.4% for liraglutide 3 mg daily over 68 weeks. The practical picture for most users looks like this: a pre-filled pen (no mixing needed), weekly dose increases from 0.6 mg up to 3.0 mg, and GI side effects that peak during titration but usually settle within a few weeks. Appetite suppression kicks in within days of the first injection. Teva's generic launched in August 2025, bringing costs down from brand Saxenda pricing (~$1,300 to $1,800 per month) to roughly $1,165 per month, with compounded options running $150 to $249.

14.9% of body weight gone in 68 weeks. That number, from the STEP 1 trial (PMID 33567185, n=1,961), turned semaglutide into the most prescribed weight loss drug in modern medicine. Semaglutide (CAS 910463-68-2) is a GLP-1 receptor agonist sold as Ozempic, Wegovy, Wegovy HD, and Rybelsus. The drug mimics incretin hormone GLP-1. It binds receptors in the pancreas, the gut, and satiety centers in the hypothalamus. Pancreatic binding increases insulin secretion. Gut binding slows gastric emptying. Brain binding turns down hunger signals. An albumin-binding fatty acid side chain extends the half-life to roughly 7 days, allowing once-weekly dosing. Real-world use spans three FDA indications. Obesity patients follow the Wegovy titration from 0.25 mg up to 2.4 mg weekly (or 7.2 mg with the high-dose label approved March 2026). Type 2 diabetics typically land between 0.5 and 2.0 mg weekly on the Ozempic label. Cardiovascular patients stay at 2.4 mg long-term after SELECT (PMID 37952131) confirmed a 20% reduction in major adverse cardiovascular events across 17,604 participants. Community experience tracks the clinical data closely. Over 350,000 combined members across r/Ozempic and r/semaglutide consistently report appetite suppression, steady 1 to 2 lbs per week weight loss, and reduced food noise within the first month. The honest caveat: two-thirds of the weight returns within a year of stopping (STEP 1 extension data). Lean mass loss of 25 to 40% without resistance training is well-documented. This is a long-term commitment, not a quick fix.

When to Choose Liraglutide

• You prefer daily dosing for more granular dose control
• Generic or compounded pricing matters ($150/month compounded vs $1,349/month brand Wegovy)
• You want the longest available safety track record (FDA-approved since 2014)
• You've had an adverse reaction to semaglutide and need an alternative GLP-1

When to Choose Semaglutide

• Once-weekly dosing is important for adherence
• Maximum weight loss is the goal (14.9% vs 8.0% in trials)
• Cardiovascular risk reduction is a priority (SELECT trial data)
• You want access to the oral tablet option (Wegovy pill, $149/month starting dose)